{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:52:05Z","timestamp":1791348725769,"version":"4.3.1"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>As pembrolizumab has been widely used in the immunotherapy of various solid tumors such as melanoma and lung cancer, reports of pembrolizumab-related adverse drug events have gradually attracted attention; however, cases of pembrolizumab-induced fulminant type 1 diabetes mellitus (FT1DM) remain rare. This article reports a case of a young male patient with clear cell renal cell carcinoma (ccRCC) and suspected pulmonary metastases, who had a prior history of hypothyroidism and no family history of diabetes. After 22 cycles of pembrolizumab treatment, the patient developed lethargy and marked metabolic acidosis. The patient had markedly elevated blood glucose with an HbA1c of 6.7% and extremely low C-peptide levels. Given the history of pembrolizumab treatment, the patient was diagnosed with immune checkpoint inhibitor-associated FT1DM. His condition improved after fluid resuscitation and insulin therapy, and he was subsequently discharged. The patient continued treatment with the same agent for another three cycles before permanent discontinuation. Given the rarity of pembrolizumab-associated FT1DM, we further reviewed the literature. A literature search identified 32 confirmed cases of pembrolizumab-associated FT1DM, which were included in the analysis. The 32 reported cases mainly involved lung cancer and melanoma, with FT1DM onset ranging from 1 to 24 treatment cycles. GADA-positive patients tended to develop FT1DM earlier. Thyroid dysfunction occurred before or concurrently with FT1DM in 90% of cases. One case of pituitary dysfunction and one case of adrenal dysfunction both occurred after FT1DM onset. These findings suggest that metabolic monitoring should continue throughout pembrolizumab therapy, and that subsequent endocrine dysfunction should be monitored after FT1DM. Pembrolizumab-associated FT1DM requires long-term insulin therapy. Whether to continue or resume pembrolizumab should be decided individually after DKA resolution and glycemic stabilization.<\/jats:p>","DOI":"10.3389\/fendo.2026.1958726","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:46:12Z","timestamp":1791348372000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pembrolizumab-induced fulminant type 1 diabetes mellitus: a case report and literature review"],"prefix":"10.3389","volume":"17","author":[{"given":"Shujun","family":"Sun","sequence":"first","affiliation":[{"name":"Weifang People\u2019s Hospital, Shandong Second Medical University","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Arrhythmia, Weifang People\u2019s Hospital, Shandong Second Medical University","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Weifang People\u2019s Hospital, Shandong Second Medical University","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Dou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Weifang People\u2019s Hospital, Shandong Second Medical University","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-019-00632-w","article-title":"Toxicities with immune checkpoint inhibitors: emerging priorities from disproportionality analysis of the FDA adverse event reporting system","volume":"14","author":"Raschi","year":"2019","journal-title":"Targeted Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1055\/a-0843-3366","article-title":"A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"De Filette","year":"2019","journal-title":"Horm Metab Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1679751","article-title":"Immune checkpoint inhibitor-associated diabetes mellitus: mechanisms, clinical manifestations, and management strategies","volume":"16","author":"Chen","year":"2026","journal-title":"Front Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40425-015-0078-9","article-title":"Pembrolizumab","volume":"3","author":"Khoja","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2023.0072","article-title":"Immune-checkpoint inhibitors-induced type 1 diabetes mellitus: from its molecular mechanisms to clinical practice","volume":"47","author":"Cho","year":"2023","journal-title":"Diabetes Metab J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12024","article-title":"Report of the committee of the Japan diabetes society on the research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus (2012)","volume":"3","author":"Imagawa","year":"2012","journal-title":"J Diabetes Investig"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-2202","article-title":"Risk factors and characteristics of checkpoint inhibitor\u2013associated autoimmune diabetes mellitus (CIADM): a systematic review and delineation from type 1 diabetes","volume":"46","author":"Wu","year":"2023","journal-title":"Diabetes Care"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.20053\/j.issn1001-5094.2022.12.004","article-title":"Research progress of immune checkpoint inhibitors","volume":"46","author":"Zhang","year":"2022","journal-title":"Prog Pharm Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101473","article-title":"Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus","volume":"24","author":"Liu","year":"2022","journal-title":"Transl Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2023.10.016","article-title":"Clinically approved monoclonal antibodies\u2013based immunotherapy: association with glycemic control and impact role of clinical pharmacist for cancer patient care","volume":"46","author":"Al-Taie","year":"2024","journal-title":"Clin Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1331","article-title":"Anti-PD1 pembrolizumab can induce exceptional fulminant type 1 diabetes","volume":"38","author":"Gaudy","year":"2015","journal-title":"Diabetes Care"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2349","article-title":"Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy","volume":"38","author":"Hughes","year":"2015","journal-title":"Diabetes Care"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-217454","article-title":"Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma","volume":"2016","author":"Aleksova","year":"2016","journal-title":"BMJ Case Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-016-0872-y","article-title":"Anti-programmed cell death 1 therapy triggering diabetic ketoacidosis and fulminant type 1 diabetes","volume":"53","author":"Kong","year":"2016","journal-title":"Acta Diabetol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.endinu.2017.01.005","article-title":"Diabetes fulminante secundaria a tratamiento con pembrolizumab","volume":"64","author":"Mizab Mellah","year":"2017","journal-title":"Endocrinol Diabetes Nutr"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000173","article-title":"Diabetic ketoacidosis as an immune-related adverse event from pembrolizumab in non\u2013small cell lung cancer","volume":"40","author":"Leonardi","year":"2017","journal-title":"J Immunother"},{"key":"B19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00262-016-1913-7","article-title":"A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes","volume":"66","author":"Chae","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jecr.2017.05.002","article-title":"Diabetic ketoacidosis after treatment with pembrolizumab","volume":"5","author":"Abdul Aziz","year":"2017","journal-title":"J Clin Transl Endocrinol Case Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11845-018-1877-z","article-title":"Irish Endocrine Society 42nd Annual Meeting, 19th and 20th October 2018 [meeting abstracts]","volume":"187","year":"2018","journal-title":"Ir J Med Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012907","article-title":"Anti-PD-1 pembrolizumab induced autoimmune diabetes in chinese patient: a case report","volume":"97","author":"Li","year":"2018","journal-title":"Med (Baltimore)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2018.10.040","article-title":"Diabetic ketoacidosis induced by a single dose of pembrolizumab","volume":"37","author":"Maamari","year":"2019","journal-title":"Am J Emerg Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00728","article-title":"Programmed cell death-1 inhibitor\u2013induced type 1 diabetes mellitus","volume":"103","author":"Clotman","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EDM-18-0153","article-title":"A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma","volume":"2019","author":"Hakami","year":"2019","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4045\/tidsskr.18.0597","article-title":"Diabetisk ketoacidose etter immunterapi mot lungekreft","volume":"136","author":"Skorpen","year":"2019","journal-title":"Tidsskr Nor Legeforen"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13065","article-title":"Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune-related adverse effect: a case report","volume":"10","author":"Edahiro","year":"2019","journal-title":"Thorac Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.eucr.2019.100849","article-title":"Fulminant type 1 diabetes mellitus induced by pembrolizumab in a patient with urothelial carcinoma: a case report","volume":"24","author":"Tohi","year":"2019","journal-title":"Urol Case Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2019.158495","article-title":"Fulminant diabetes due to immune checkpoint inhibitors in the emergency department","volume":"38","author":"Peyrony","year":"2020","journal-title":"Am J Emerg Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-018-1234-8","article-title":"Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype","volume":"56","author":"Marchand","year":"2019","journal-title":"Acta Diabetol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1673","article-title":"Detailed time course of decline in serum C-peptide levels in anti\u2013programmed cell death-1 therapy\u2013induced fulminant type 1 diabetes","volume":"42","author":"Saito","year":"2019","journal-title":"Diabetes Care"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00014","article-title":"Immune checkpoint inhibitor-induced diabetic ketoacidosis: a report of four cases and literature review","volume":"11","author":"Hong","year":"2020","journal-title":"Front Endocrinol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-020-02502-w","article-title":"Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report","volume":"14","author":"Porntharukchareon","year":"2020","journal-title":"J Med Case Rep"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EDM-19-0152","article-title":"Pembrolizumab-induced fulminant type 1 diabetes with C-peptide persistence at first referral","volume":"2020","author":"Kusuki","year":"2020","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"B35","first-page":"62","article-title":"Two case reports of immune checkpoint inhibitors induced type 1 diabetes and literature review","volume":"28","author":"Zhang","year":"2020","journal-title":"Chin J Diabetes"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0222","article-title":"A case of pembrolizumab-induced fulminant type 1 diabetes mellitus in breast cancer","volume":"13","author":"Tang","year":"2021","journal-title":"Immunotherapy"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2020-0054","article-title":"Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus","volume":"20","author":"Kyriacou","year":"2020","journal-title":"Clin Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12659\/AJCR.931702","article-title":"A severe case of diabetic ketoacidosis and new-onset type 1 diabetes mellitus associated with anti-glutamic acid decarboxylase antibodies following immunotherapy with pembrolizumab","volume":"22","author":"Kedzior","year":"2021","journal-title":"Am J Case Rep"},{"key":"B39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1530\/EDM-21-0123","article-title":"New onset autoimmune diabetes mellitus and hypothyroidism secondary to pembrolizumab in a patient with metastatic lung cancer","volume":"2022","author":"Cunha","year":"2022","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.55729\/2000-9666.1270","article-title":"When hormones are being difficult: a rare case and the literature review of pembrolizumab-induced polyendocrinopathy","volume":"13","author":"Tayyeb","year":"2023","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7759\/cureus.35276","article-title":"A case of pembrolizumab-induced diabetic ketoacidosis and hyperthyroidism in a patient with recurrent esophageal adenocarcinoma","volume":"15","author":"Salangsang","year":"2023","journal-title":"Cureus"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v14.i11.535","article-title":"Autoimmune diabetes from pembrolizumab: a case report and review of literature","volume":"14","author":"Bhanderi","year":"2023","journal-title":"World J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7759\/cureus.76687","article-title":"Fulminant type 1 diabetes mellitus leading to diabetic ketoacidosis and mesenteric ischemia with necrosis following pembrolizumab administration: a case report","volume":"16","author":"Ueki","year":"2024","journal-title":"Cureus"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7759\/cureus.90999","article-title":"Endocrine crisis triggered by pembrolizumab: a case of acute-onset diabetes with diabetic ketoacidosis","volume":"17","author":"Raphael","year":"2025","journal-title":"Cureus"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1958726\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:46:20Z","timestamp":1791348380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1958726\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":44,"alternative-id":["10.3389\/fendo.2026.1958726"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1958726","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"1958726"}}